BioCentury
ARTICLE | Clinical News

GTI-2040: Phase II started

September 3, 2007 7:00 AM UTC

LOR began an open-label, dose-escalation, U.S. Phase II trial of GTI-2040 plus cytarabine (araC) in 60 refractory or relapsed AML patients. ...